Literature DB >> 27161972

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Elena I Pentsova1, Ronak H Shah1, Jiabin Tang1, Adrienne Boire1, Daoqi You1, Samuel Briggs1, Antonio Omuro1, Xuling Lin1, Martin Fleisher1, Christian Grommes1, Katherine S Panageas1, Fanli Meng1, S Duygu Selcuklu1, Shahiba Ogilvie1, Natalie Distefano1, Larisa Shagabayeva1, Marc Rosenblum1, Lisa M DeAngelis1, Agnes Viale1, Ingo K Mellinghoff2, Michael F Berger1.   

Abstract

PURPOSE: Cancer spread to the central nervous system (CNS) often is diagnosed late and is unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS are largely unknown because of limited access to tumor tissue.
MATERIALS AND METHODS: We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained through routine lumbar puncture in 53 patients with suspected or known CNS involvement by cancer.
RESULTS: We detected high-confidence somatic alterations in 63% (20 of 32) of patients with CNS metastases of solid tumors, 50% (six of 12) of patients with primary brain tumors, and 0% (zero of nine) of patients without CNS involvement by cancer. Several patients with tumor progression in the CNS during therapy with inhibitors of oncogenic kinases harbored mutations in the kinase target or kinase bypass pathways. In patients with glioma, the most common malignant primary brain tumor in adults, examination of cell-free DNA uncovered patterns of tumor evolution, including temozolomide-associated mutations.
CONCLUSION: The study shows that CSF harbors clinically relevant genomic alterations in patients with CNS cancers and should be considered for liquid biopsies to monitor tumor evolution in the CNS.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27161972      PMCID: PMC4981784          DOI: 10.1200/JCO.2016.66.6487

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  61 in total

1.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Authors:  Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.

Authors:  Masato Shingyoji; Hajime Kageyama; Tsukasa Sakaida; Takahiro Nakajima; Yukiko Matsui; Meiji Itakura; Toshihiko Iuchi; Sana Yokoi; Hideki Kimura; Toshihiko Iizasa
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

3.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

4.  Brain tumor mutations detected in cerebral spinal fluid.

Authors:  Wenying Pan; Wei Gu; Seema Nagpal; Melanie Hayden Gephart; Stephen R Quake
Journal:  Clin Chem       Date:  2015-01-20       Impact factor: 8.327

5.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

7.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

8.  Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Authors:  Sumitra Mohan; Ellen Heitzer; Peter Ulz; Ingrid Lafer; Sigurd Lax; Martina Auer; Martin Pichler; Armin Gerger; Florian Eisner; Gerald Hoefler; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  PLoS Genet       Date:  2014-03-27       Impact factor: 6.020

9.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Authors:  Heike Niessner; Andrea Forschner; Bernhard Klumpp; Jürgen B Honegger; Maria Witte; Antje Bornemann; Reinhard Dummer; Annemarie Adam; Jürgen Bauer; Ghazaleh Tabatabai; Keith Flaherty; Tobias Sinnberg; Daniela Beck; Ulrike Leiter; Cornelia Mauch; Alexander Roesch; Benjamin Weide; Thomas Eigentler; Dirk Schadendorf; Claus Garbe; Dagmar Kulms; Leticia Quintanilla-Martinez; Friedegund Meier
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

View more
  120 in total

1.  Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.

Authors:  Shenpeng Ying; Honggang Ke; Yan Ding; Yanmei Liu; Xiaowan Tang; Dongyong Yang; Min Li; Junjun Liu; Bing Yu; Jianxing Xiang; Xinru Mao; Han Han-Zhang; Wei Hu; Lili Chen
Journal:  Cancer Biol Ther       Date:  2018-11-05       Impact factor: 4.742

Review 2.  Circulating cell-free DNA for non-invasive cancer management.

Authors:  Caitlin M Stewart; Dana W Y Tsui
Journal:  Cancer Genet       Date:  2018-03-11

3.  Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Authors:  Christian Grommes; Sarah S Tang; Julia Wolfe; Thomas J Kaley; Mariza Daras; Elena I Pentsova; Anna F Piotrowski; Jacqueline Stone; Andrew Lin; Craig P Nolan; Malbora Manne; Paolo Codega; Carl Campos; Agnes Viale; Alissa A Thomas; Michael F Berger; Vaios Hatzoglou; Anne S Reiner; Katherine S Panageas; Lisa M DeAngelis; Ingo K Mellinghoff
Journal:  Blood       Date:  2018-12-19       Impact factor: 22.113

4.  Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.

Authors:  Chi-Lu Chiang; Cheng-Chia Lee; Hsu-Ching Huang; Chia-Hung Wu; Yi-Chen Yeh; Chia-I Shen; Yung-Hung Luo; Tsu-Hui Shiao; Han Jhih Chang; Yu-Ting Huang; Yuh-Min Chen; Teh-Ying Chou; Chao-Hua Chiu
Journal:  Target Oncol       Date:  2021-02-10       Impact factor: 4.493

5.  Management of brain metastases from renal cell carcinoma.

Authors:  Suguru Shirotake
Journal:  Ann Transl Med       Date:  2019-12

Review 6.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

Review 7.  Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies.

Authors:  Kerry J Savage
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

9.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

Review 10.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.